Rein Therapeutics (RNTX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	17.68 mm	17.68 mm	17.68 mm	17.68 mm	17.68 mm	17.68 mm
Cash burn (monthly)	1.42 mm	(no burn)	2.02 mm	2.47 mm	1.27 mm	2.32 mm
Cash used (since last report)	7.56 mm	n/a	10.76 mm	13.12 mm	6.77 mm	12.35 mm
Cash remaining	10.12 mm	n/a	6.91 mm	4.56 mm	10.91 mm	5.33 mm
Runway (months of cash)	7.1	n/a	3.4	1.8	8.6	2.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

RNTX institutional ownership history Ownership history

34.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	33	23	+43.5%
Opened positions	16	7	+128.6%
Closed positions	6	13	-53.8%
Increased positions	4	3	+33.3%
Reduced positions	3	5	-40.0%

13F shares	Current	Prev Q	Change
Total value	11.64 bn	9.75 bn	+19.5%
Total shares	7.46 mm	4.19 mm	+77.8%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BIOS Capital Management	1.69 mm	$3.89 bn	NEW
Novartis Bioventures	1.20 mm	$765.00 k	0.0%
University Of Texas/texas Am Investment Managment	960.67 k	$0.00	-31.5%
Voss Capital	956.20 k	$2.20 bn	NEW
Vanguard	424.99 k	$977.49 mm	-1.7%
Cable Car Capital	420.00 k	$966.00 mm	NEW
Prosight Management	404.98 k	$931.45 mm	NEW
Geode Capital Management	241.44 k	$555.48 mm	+5.1%
Biotechnology Value Fund L P	236.84 k	$0.00	0.0%
Sigma Planning	236.21 k	$543.28 mm	+11.2%

Largest transactions	Shares	Bought/sold	Change
BIOS Capital Management	1.69 mm	+1.69 mm	NEW
Voss Capital	956.20 k	+956.20 k	NEW
University Of Texas/texas Am Investment Managment	960.67 k	-442.67 k	-31.5%
Cable Car Capital	420.00 k	+420.00 k	NEW
Prosight Management	404.98 k	+404.98 k	NEW
RY Royal Bank of Canada	106.97 k	+106.97 k	NEW
Exencial Wealth Advisors	30.53 k	+30.53 k	NEW
BlackRock	78.95 k	+27.67 k	+54.0%
Texas Capital Bank Wealth Management Services	26.17 k	+26.17 k	NEW
Newbridge Financial Services	0.00	-25.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RNTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Dec 24	James Brian Windsor	Common Stock	Buy	Acquire P	Yes	No	2.25	161	362.25	161
5 Dec 24	James Brian Windsor	Common Stock	Buy	Acquire P	Yes	No	2.24	239	535.36	239
2 Dec 24	James Brian Windsor	Stock Option Common Stock	Grant	Acquire A	No	No	2.85	517,500	1.47 mm	517,500
2 Dec 24	Ambros Reinhard J.	Stock Option Common Stock	Grant	Acquire A	No	No	2.85	35,000	99.75 k	35,000
2 Dec 24	Alan A Musso	Stock Option Common Stock	Grant	Acquire A	No	No	2.85	35,000	99.75 k	35,000
2 Dec 24	Von Rickenbach Josef H	Stock Option Common Stock	Grant	Acquire A	No	No	2.85	35,000	99.75 k	35,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Pre-Market Session

24 Jan 25

Aileron Therapeutics Announces Rebranding To Rein Therapeutics; Company Shares To Begin Trading On Nasdaq Under The Trading Symbol "RNTX" Effective January 13, 2025

10 Jan 25

Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assetsCompany shares to begin trading

Press releases

From Benzinga Pro

Aileron Therapeutics Announces Rebranding to Rein Therapeutics

10 Jan 25